|
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The authors conducted a cohort study to evaluate the effectiveness and safety of half-dose CS plus renin-angiotensin system blockers (RASB) (CS + RASB) <i>versus</i> full-dose CS in IgAN patients.
|
31762966 |
2019 |
|
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Angiotensin converting enzyme inhibitor (ACEI) and angiotensin receptor blocker (ARB) as the commonly used renin-angiotensin aldosterone system inhibitor are widely used in patients with IgA nephropathy (IgAN), but the effect is controversy.
|
31700813 |
2019 |
|
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
This is a case-control study.Ninety-two patients with IgAN who received HCQ in addition to routine renin-angiotensin-aldosterone system inhibitors (RAASi) therapy were included.
|
31382914 |
2019 |
|
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The beneficial effects of renin-angiotensin system inhibitors (RASI) on IgA nephropathy with tubulointerstitial lesions categorized by Oxford classification.
|
30796546 |
2019 |
|
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Expression of the intrarenal angiotensin receptor and the role of renin-angiotensin system inhibitors in IgA nephropathy.
|
30159797 |
2019 |
|
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Despite optimization of renin-angiotensin-aldosterone system (RAAS) inhibition, patients with immunoglobulin A nephropathy (IgAN) and persistent proteinuria remain at risk for kidney failure.
|
30922594 |
2019 |
|
IGA Glomerulonephritis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Night-time activation of the intrarenal renin-angiotensin system due to nocturnal hypertension is associated with renal arteriosclerosis in normotensive IgA nephropathy patients.
|
29507351 |
2018 |
|
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Fifty years into the original description of IgA nephropathy, there is still no specific therapy for this condition and general measures including blood pressure control with blockers of the renin-angiotensin-aldosterone system and salt restriction remain the cornerstone to slow disease progression.
|
30177025 |
2018 |
|
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The treatment of IgA nephropathy (IgAN) has been limited by several controversies in the literature, including the benefits of corticosteroids in addition to optimized renin-angiotensin system blockers (RASBs), in those with lower estimated glomerular filtration rate (eGFR), or in different ethnic groups.
|
28399021 |
2017 |
|
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The Therapeutic Evaluation of Steroids in IgA Nephropathy Global (TESTING) study was a multicenter, double-blind, randomized clinical trial designed to recruit 750 participants with IgA nephropathy (proteinuria greater than 1 g/d and estimated glomerular filtration rate [eGFR] of 20 to 120 mL/min/1.73 m2 after at least 3 months of blood pressure control with renin-angiotensin system blockade] and to provide follow-up until 335 primary outcomes occurred.
|
28763548 |
2017 |
|
IGA Glomerulonephritis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
ACE insertion/deletion polymorphism (rs1799752) modifies the renoprotective effect of renin-angiotensin system blockade in patients with IgA nephropathy.
|
24452035 |
2015 |
|
IGA Glomerulonephritis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Genetic polymorphisms of the renin-angiotensin system have been reported to be related to the clinical outcomes in immunoglobulin A nephropathy (IgAN).
|
21150220 |
2011 |
|
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Inhibition of the renin-angiotensin-aldosterone system (RAAS) slows down the progression of chronic renal diseases (CKD) including IgA nephropathy (IgAN).
|
21974877 |
2011 |
|
IGA Glomerulonephritis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Genetic polymorphisms of the renin-angiotensin-aldosterone system in Chinese patients with end-stage renal disease secondary to IgA nephropathy.
|
21163122 |
2010 |
|
IGA Glomerulonephritis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our findings implicate that local renin angiotensin system activation in podocytes is partly involved in down-regulation of nephrin by mesangial medium in IgA nephropathy.
|
19397686 |
2009 |
|
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we explore thiazolidinediones as new therapeutic additives to established treatment regime of renin angiotensin blockade in IgAN.
|
19443277 |
2009 |
|
IGA Glomerulonephritis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Polymorphism of renin-angiotensin system genes in IgA nephropathy.
|
15504143 |
2004 |
|
IGA Glomerulonephritis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Influence of genetic polymorphisms of the renin-angiotensin system on IgA nephropathy.
|
15031629 |
2004 |
|
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Enhanced gene expression for the renin-angiotensin system (RAS) is detected in glomerular mesangial cells in IgA nephropathy (IgAN).
|
15458433 |
2004 |
|
IGA Glomerulonephritis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The effects of polymeric IgA1 (pIgA1) and monomeric IgA1 (mIgA1) from patients with IgA nephropathy (IgAN) on the renin-angiotensin system (RAS) and TGF-beta synthesis were examined in cultured human mesangial cells (HMC).
|
14638911 |
2003 |
|
IGA Glomerulonephritis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The gene polymorphism studies for human leukocyte antigen (HLA), renin-angiotensin-aldosterone system, and selectin gene clusters, suggest a certain degree of genetic predisposition in patients for IgA nephropathy.
|
14631563 |
2003 |
|
IGA Glomerulonephritis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Precocious activation of genes of the renin-angiotensin system and the fibrogenic cascade in IgA glomerulonephritis.
|
12787405 |
2003 |
|
IGA Glomerulonephritis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We could not confirm an association between IgA nephropathy and polymorphisms of genes involved in the renin-angiotensin system.
|
12552499 |
2003 |
|
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Angiotensinogen gene variation and renoprotective efficacy of renin-angiotensin system blockade in IgA nephropathy.
|
12911556 |
2003 |
|
IGA Glomerulonephritis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Polymorphisms of renin-angiotensin system genes in childhood IgA nephropathy.
|
11354780 |
2001 |